Faculty Profiles - KATSUYAMA Takayuki

Papers - KATSUYAMA Takayuki

Division display 81 - 88 of about 88 ／ All the affair displays >>

Current concept and epidemiology of systemic vasculitides. Invited Reviewed International journal

Takayuki Katsuyama, Ken-Ei Sada, Hirofumi Makino

Allergology international : official journal of the Japanese Society of Allergology 63 ( 4 ) 505 - 13 2014.12

Authorship：Lead author Language：English Publishing type：Research paper (scientific journal)

Although a new classification algorithm for systemic vasculitides was proposed by Watts et al. and the Chapel Hill Consensus Conference (CHCC) was updated in 2012, there are currently no validated diagnostic criteria for systemic vasculitides. The Diagnostic and Classification Criteria for Vasculitis study (DCVAS) is a global study to develop and improve the diagnostic criteria for systemic vasculitides. The epidemiology of systemic vasculitides differs widely among countries. For example, in the case of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, patients with microscopic polyangiitis (MPA) and with positivity for MPO-ANCA are predominant in Asian countries, whereas patients with granulomatosis with polyangiitis (GPA) and with positivity for PR3-ANCA are predominant in northern Europe and the United States. Interstitial lung disease (ILD) occurs more frequently in Asian patients compared with patients in Europe. The incidence and the prevalence of large-vessel vasculitis also differ significantly. Giant cell arteritis (GCA) occurs frequently in northern Europe, unlike Takayasu arteritis (TAK). The ethnic and regional differences in the incidence, prevalence and clinical characteristics of patients with vasculitis should be recognized when we diagnose and treat patients with vasculitis using criteria, and should also be considered when interpreting the results from clinical studies.

DOI： 10.2332/allergolint.14-RAI-0778

PubMed

researchmap

Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Reviewed International journal

Takayuki Katsuyama, Kazuyoshi Saito, Satoshi Kubo, Masao Nawata, Yoshiya Tanaka

Arthritis research & therapy 16 ( 1 ) R43 2014.2

Authorship：Lead author Language：English Publishing type：Research paper (scientific journal)

INTRODUCTION: Pneumocystis pneumonia (PCP) is one of the most prevalent opportunistic infections in patients undergoing immunosuppressive therapy. In this article, we discuss risk factors for PCP development in patients with rheumatoid arthritis (RA) during the course of biologic therapy and describe a prophylactic treatment for PCP with trimethoprim/sulfamethoxazole (TMP/SMX). We also evaluate the effectiveness and safety of the treatment. METHODS: We retrospectively analyzed 702 RA patients who received biologic therapy and compared the characteristics of patients with vs. without PCP to identify the risk factors for PCP. Accordingly, we analyzed 214 patients who received the TMP/SMX biologic agents as prophylaxis against PCP at the start of treatment to evaluate their effectiveness and safety. RESULTS: We identified the following as risk factors for PCP: age at least 65 years (hazard ratio (HR) = 4.37, 95% confidence interval (CI) = 1.04 to 18.2), coexisting pulmonary disease (HR = 8.13, 95% CI = 1.63 to 40.0), and use of glucocorticoids (HR = 11.4, 95% CI = 1.38 to 90.9). We employed a protocol whereby patients with two or three risk factors for PCP would receive prophylactic treatment. In the study with 214 patients, there were no cases of PCP, and the incidence of PCP was reduced to 0.00 per 100 person-years compared with that before the procedure (0.93 per 100 person-years). There were no severe adverse events induced by the TMP/SMX treatment. CONCLUSIONS: RA patients with two or three risk factors for PCP who are receiving biologic therapy can benefit from safe primary prophylaxis.

DOI： 10.1186/ar4472

PubMed

researchmap

Epiglottic aphthous ulcers.

Hideharu Hagiya, Hiroyuki Hanakawa, Takayuki Katsuyama, Fumio Otsuka

Internal medicine (Tokyo, Japan) 53 ( 15 ) 1731 - 1731 2014

[Analysis of the relationship between polymyalgia rheumatica and matrix metalloproteinase-3 levels during the first medical examination and during treatment].

Kouhei Miyake, Takayuki Katsuyama

Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 37 ( 1 ) 48 - 54 2014

Language：Japanese Publishing type：Research paper (scientific journal)

In the present study, we assessed the relationship between polymyalgia rheumatica (PMR) and matrix metalloproteinase-3 (MMP-3) levels during the first medical examination and during treatment. We examined 22 patients with PMR in our hospital from 2010 to 2012, in whom the diagnosis was confirmed by the 2012 Provisional Classification Criteria for PMR. The MMP-3 levels were obtained from 19 patients, and the average MMP-3 level was 200.8 ng/mL; this level increased in 15 patients. During the 1 month after treatment initiation, the average dose of prednisolones (PSL) was increased from 2.75 mg/day to 11.3 mg/day, whereas the C-reactive protein level decreased from 6.92 mg/dL to 0.33 mg/dL; however, the average MMP-3 levels increased to 225.1 ng/mL during this period. When comparing the 7 patients in whom PSL withdrawal was achieved within 1 year and the patients in whom PSL withdrawal was difficult, we noted that the MMP-3 levels were higher in the patients in whom PSL withdrawal was difficult, and the MMP-3 level at 3 months after the first medical examination was significantly higher compared to the MMP-3 level during the first medical examination (p = 0.011). Although the MMP-3 level is influenced by PSL use, the MMP-3 levels may be considered to reflect the disease activity of PMR. Thus, MMP-3 levels may be a useful predictive factor for the success of PSL withdrawal in patients with PMR.

PubMed

researchmap

Large vessel vasculitis with myelodysplastic syndrome. Reviewed

Takayuki Katsuyama, Haruhito Adam Uchida, Kishio Toma, Yoshinobu Maeda, Daisho Hirota, Ryoko Umebayashi, Ken-Ei Sada, Hirofumi Makino

Internal medicine (Tokyo, Japan) 53 ( 1 ) 63 - 6 2014

Authorship：Lead author Language：English Publishing type：Research paper (scientific journal)

A 71-year-old woman presented with a high-grade fever, neck pain, anemia and thrombocytopenia. After performing further examinations, we concluded that she had simultaneously developed large vessel vasculitis and myelodysplastic syndrome (MDS). Although glucocorticoid administration improved her clinical symptoms, the MDS transformed into acute myeloid leukemia and she died one year after receiving the diagnosis. The occurrence of immune-mediated disorders in patients with MDS is a well-known phenomenon; however, large vessel vasculitis is a rare complication of MDS. Our case suggests that the association between systemic vasculitis and MDS may result in poor outcomes.

PubMed

researchmap

Estrogen facilitates osteoblast differentiation by upregulating bone morphogenetic protein-4 signaling. Reviewed International journal

Yoshinori Matsumoto, Fumio Otsuka, Mariko Takano-Narazaki, Takayuki Katsuyama, Eri Nakamura, Naoko Tsukamoto, Kenichi Inagaki, Ken-Ei Sada, Hirofumi Makino

Steroids 78 ( 5 ) 513 - 20 2013.5

Language：English Publishing type：Research paper (scientific journal)

Imbalanced functions of osteoclasts and osteoblasts are involved in various types of bone damage including postmenopausal osteoporosis. In the present study, we investigated the cellular mechanism by which estrogen interacts in the process of osteoblastic differentiation regulated by BMP-4 using mouse MC3T3-E1 cells that express estrogen receptors (ER) and BMP-4. Estradiol enhanced BMP-4-induced Runx2, osterix, ALP and osteocalcin expression in MC3T3-E1 cells. BMP-4-induced mineralization shown by Alizarin red staining was also facilitated by estrogen treatment. It was revealed that estrogen upregulated BMP-4-induced Smad1/5/8 phosphorylation, BRE-Luc activity and Id-1 mRNA expression. The expression of BMPRII was increased by estrogen in MC3T3-E1 cells, and inhibition of BMPRII or ALK-2/3 signaling impaired the effect of estrogen on BMP-4 signaling. Of note, the enhanced expression of osterix, ALP and osteocalcin mRNAs induced by BMP-4 and estrogen was reversed in the presence of an ER antagonist. Given that membrane-impermeable estrogen also upregulated BMP-4-induced expression of osteoblastic markers and Id-1 mRNA, non-genomic ER activity is involved in the mechanism by which estrogen enhances BMP-4-induced osteoblast differentiation in MC3T3-E1 cells. On the other hand, the expression of ERα and endogenous BMP-4 was suppressed by BMP-4 treatment regardless of the presence of estrogen, implying the presence of a negative feedback loop for osteoblast differentiation. Thus, estrogen is functionally involved in the process of osteoblast differentiation regulated by BMP-4 through upregulating BMP sensitivity of MC3T3-E1 cells.

DOI： 10.1016/j.steroids.2013.02.011

PubMed

researchmap

Rapid progression of Graves' ophthalmopathy despite the administration of thiamazole. Reviewed

Takayuki Katsuyama, Masaya Takeda, Fumio Otsuka, Kishio Toma, Kenichi Inagaki, Ken-Ei Sada, Yukari Mimura, Toshio Ogura, Hirofumi Makino

Internal medicine (Tokyo, Japan) 52 ( 20 ) 2317 - 20 2013

Authorship：Lead author Language：English Publishing type：Research paper (scientific journal)

A 42-year-old female with body weight loss, finger tremors and ocular discomfort was diagnosed with Graves' disease complicated with ophthalmopathy. Thiamazole therapy rapidly improved her hyperthyroidism. However, she was admitted to our hospital because her eye symptoms acutely deteriorated over a period of two weeks. She had ocular immotility, exposure keratitis, conjunctival edema, severe proptosis and visual impairment with a high titer of serum thyroid-stimulating antibody (TSAb). Methylprednisolone pulse therapy at a dose of 500 mg/day improved her eye symptoms. Although the mechanism of the progression of Graves' ophthalmopathy has not yet been elucidated, special attention should be paid to the occurrence of ophthalmopathy even after the initiation of thiamazole therapy.

PubMed

researchmap

Acquired haemophilia in a patient with castleman's disease: a case report Reviewed

T. Katsuyama, K. E. Sada, A. Katayama, N. Hinamoto, H. Wakabayashi, T. Kawabata, H. Makino

HAEMOPHILIA 18 ( 4 ) e360 - e362 2012.7

　 PREV - NEXT 　

< KATSUYAMA Takayuki >

Papers - KATSUYAMA Takayuki